68 % of the outcomes reported showed that clinical pharmacy services were associated with better improvement in patients ' outcomes compared with the control group .
The involvement of a pharmacist demonstrated an ability to improve CVD outcomes through providing educational intervention , medicine management intervention , or a combination of both .
These interventions result ed in improved CVD risk factors , improved patient outcomes , and reduced number of drug-related problems with a direct effect on CVD control .
These improvements may lead to an improvement in patient quality of life , better use of health care re sources , and a reduced rate of mortality
BACKGROUND Cardiovascular disease ( CVD ) is considered to be the main cause of death and one of the most common diseases affecting health care systems worldwide .
Many methods have been used to improve CVD outcomes , one of which is to involve clinical pharmacists in the direct care of patients with CVD .
OBJECTIVE To perform a systematic review assessing the effectiveness of clinical pharmacist interventions within a multidisciplinary team in the secondary prevention of CVD , using studies conducted on patients with heart failure , coronary heart disease , or those with CVD risk factors .
Pharmacist's contribution in a heart function clinic: patient perception and medication appropriateness.
BACKGROUND It has been cited that the management of congestive heart failure ( CHF ) requires a multidisciplinary approach ; however , the role of the pharmacist has not been extensively studied . The roles for pharmacists are changing to meet the long term needs of patients in the community setting , including patients with CHF . OBJECTIVES To evaluate the effect of a pharmacist on the appropriateness of medications taken by patients in the heart function clinic using the Medication Appropriateness Index ( MAI ) and to measure the effect of a pharmacist on the patients ' response to the pharmacist 's interventions using the Purdue Directive Guidance ( DG ) scale . METHODS Eighty patients attending the heart function clinic at The University Health Network , Toronto General Hospital Toronto , Ontario were r and omly assigned to an intervention group that received pharmacist services or a nonintervention group that received usual care from the clinic staff . Patients were assessed at baseline and at one-month follow-up . RESULTS The change in MAI score from baseline was 0.74 and 0.49 for the intervention and nonintervention groups , respectively ( P=0.605 ) . The change in DG survey results was 9.97 and 1.00 for the intervention and nonintervention groups , respectively ( P<0.001 ) . The intervention group improved significantly in all components of the DG survey , especially those pertaining to feedback and goal setting . CONCLUSIONS A benefit was demonstrated for ' directive guidance ' of patients , in the form of education and goal setting as shown by positive survey results
68 % of the outcomes reported showed that clinical pharmacy services were associated with better improvement in patients ' outcomes compared with the control group .
The involvement of a pharmacist demonstrated an ability to improve CVD outcomes through providing educational intervention , medicine management intervention , or a combination of both .
These interventions result ed in improved CVD risk factors , improved patient outcomes , and reduced number of drug-related problems with a direct effect on CVD control .
These improvements may lead to an improvement in patient quality of life , better use of health care re sources , and a reduced rate of mortality
BACKGROUND Cardiovascular disease ( CVD ) is considered to be the main cause of death and one of the most common diseases affecting health care systems worldwide .
Many methods have been used to improve CVD outcomes , one of which is to involve clinical pharmacists in the direct care of patients with CVD .
OBJECTIVE To perform a systematic review assessing the effectiveness of clinical pharmacist interventions within a multidisciplinary team in the secondary prevention of CVD , using studies conducted on patients with heart failure , coronary heart disease , or those with CVD risk factors .